Skip to content

Study · Animal study (in vivo) · dog · 1996

7 results

Sixteen weeks of hexarelin therapy in aged dogs: effects on the somatotropic axis, muscle morphology, and bone metabolism.

Cella SG, Cerri CG, Daniel S, Sibilia V, Rigamonti A, Cattaneo L, Deghenghi R, Müller EE

The journals of gerontology. Series A, Biological sciences and medical sciences1 Nov 1996Cited by 11 (Europe PMC)

PMID8914494 (opens in a new tab)DOI10.1093/gerona/51a.6.b439 (opens in a new tab)PepBankPUB-08914494
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In old beagle dogs, the GH peak response to hexarelin first increased and then dropped to pretreatment values during each on-drug period.

    In plain wordsIn old dogs, the growth hormone rise to hexarelin first grew and then fell back to its starting level during each treatment period.

    Peptide
    Hexarelin
    Outcome
    MixedGH peak response to hexarelin during each on-drug period
    Study

    dogn = 6

    Old beagle dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    500 micrograms/kg/day · subcutaneous · 16 weeksAs given in this study (dog).

    Source sentences

    Summary
    During each on period, the growth hormone (GH) peak response to HEXA initially increased and then dropped to pretreatment values.
    2 context sentences
    Summary · context
    Hexarelin (HEXA; 500 micrograms/kg/die, s.c.) was administered for 16 weeks to six old beagle dogs.
    Summary · context
    The treatment consisted of three on-drug periods spaced by two off-drug periods.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In old beagle dogs, a wash-out interval restored the same pattern of GH responsiveness each time.

    In plain wordsIn old dogs, a break in treatment brought back the same growth hormone response pattern each time.

    Peptide
    Hexarelin
    Outcome
    MixedGH responsiveness after wash-out
    Study

    dogn = 6

    Old beagle dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    500 micrograms/kg/day · subcutaneous · 16 weeksAs given in this study (dog).

    Source sentences

    Summary
    Each time, a wash-out interval restored the same pattern of GH responsiveness.
    2 context sentences
    Summary · context
    Hexarelin (HEXA; 500 micrograms/kg/die, s.c.) was administered for 16 weeks to six old beagle dogs.
    Summary · context
    The treatment consisted of three on-drug periods spaced by two off-drug periods.
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In old beagle dogs, hexarelin significantly augmented the indices of spontaneous GH pulsatility.

    In plain wordsIn old dogs, hexarelin increased the natural pulses of growth hormone.

    Peptide
    Hexarelin
    Outcome
    IncreaseSpontaneous GH pulsatility
    Study

    dogn = 6

    Old beagle dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    500 micrograms/kg/day · subcutaneous · 16 weeksAs given in this study (dog).

    Source sentences

    Summary
    HEXA significantly augmented the indices of spontaneous pulsatility of GH
    2 context sentences
    Summary · context
    Hexarelin (HEXA; 500 micrograms/kg/die, s.c.) was administered for 16 weeks to six old beagle dogs.
    Summary · context
    The treatment consisted of three on-drug periods spaced by two off-drug periods.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In old beagle dogs, plasma insulin-like growth factor I levels did not change during hexarelin treatment.

    In plain wordsIn old dogs, hexarelin treatment did not change IGF-I levels in the blood.

    Peptide
    Hexarelin
    Outcome
    No significant changePlasma IGF-I
    Study

    dogn = 6

    Old beagle dogs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    500 micrograms/kg/day · subcutaneous · 16 weeksAs given in this study (dog).

    Source sentences

    Summary
    but plasma insulin-like growth factor I levels did not change during treatment.
    2 context sentences
    Summary · context
    Hexarelin (HEXA; 500 micrograms/kg/die, s.c.) was administered for 16 weeks to six old beagle dogs.
    Summary · context
    The treatment consisted of three on-drug periods spaced by two off-drug periods.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In old beagle dogs, hexarelin significantly decreased the urinary concentration of lysylpyridinoline, a bone matrix component.

    In plain wordsIn old dogs, hexarelin lowered a urine marker of bone breakdown.

    Peptide
    Hexarelin
    Outcome
    DecreaseUrinary lysylpyridinoline (bone resorption marker)
    Study

    dogn = 6

    Old beagle dogs
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    500 micrograms/kg/day · subcutaneous · 16 weeksAs given in this study (dog).

    Source sentences

    Summary
    HEXA apparently reduced bone resorption since it significantly decreased the urinary concentration of lysylpyridinoline, a bone matrix component.
    2 context sentences
    Summary · context
    Hexarelin (HEXA; 500 micrograms/kg/die, s.c.) was administered for 16 weeks to six old beagle dogs.
    Summary · context
    The treatment consisted of three on-drug periods spaced by two off-drug periods.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In old beagle dogs, alkaline phosphatase levels were unchanged during hexarelin treatment.

    In plain wordsIn old dogs, hexarelin did not change a blood marker of bone formation.

    Peptide
    Hexarelin
    Outcome
    No significant changeAlkaline phosphatase (bone formation marker)
    Study

    dogn = 6

    Old beagle dogs
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    500 micrograms/kg/day · subcutaneous · 16 weeksAs given in this study (dog).

    Source sentences

    Summary
    Bone formation apparently was not affected since unchanged levels of alkaline phosphatase were recorded.
    2 context sentences
    Summary · context
    Hexarelin (HEXA; 500 micrograms/kg/die, s.c.) was administered for 16 weeks to six old beagle dogs.
    Summary · context
    The treatment consisted of three on-drug periods spaced by two off-drug periods.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In three of six old beagle dogs, hexarelin improved some morphological and biochemical muscle indices, which stayed unchanged in young untreated controls.

    In plain wordsIn three of six old dogs, hexarelin improved some muscle measures, while muscle in young untreated dogs stayed the same.

    Peptide
    Hexarelin
    Outcome
    IncreaseMuscle morphological and biochemical indices
    Study

    dogn: not reported in source

    Old beagle dogs
    Comparator
    Young untreated controls
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    500 micrograms/kg/day · subcutaneous · 16 weeksAs given in this study (dog).

    Source sentences

    Summary
    In three of six old dogs, HEXA induced an improvement of some morphological and biochemical muscular indices, evaluated in muscle specimens that, instead, remained unchanged in a group of young untreated controls.
    2 context sentences
    Summary · context
    Hexarelin (HEXA; 500 micrograms/kg/die, s.c.) was administered for 16 weeks to six old beagle dogs.
    Summary · context
    The treatment consisted of three on-drug periods spaced by two off-drug periods.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.